SIREN : 344285184
MBBS is a French company founded 38 years ago, specialized in the sector Autres intermédiaires du commerce en produits divers. Based in PARIS (75002), this company of category PME shows in 2022 a revenue of 44.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2022 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Revenue | 44 601 715 € | 59 538 739 € | 78 012 016 € | 52 221 743 € |
| Net income | 906 447 € | 573 924 € | 1 133 815 € | 3 709 € |
| EBITDA | 1 181 414 € | 1 281 214 € | 2 170 421 € | 535 168 € |
| Net margin | 2.0% | 1.0% | 1.5% | 0.0% |
In 2022, MBBS achieves revenue of 44.6 M€. Activity remains stable over the period (CAGR: -2.6%). Significant drop of -25% vs 2018. After deducting consumption (15.5 M€), gross margin stands at 29.1 M€, i.e. a rate of 65%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.2 M€, representing 2.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 906 k€, i.e. 2.0% of revenue. This profit can be retained or distributed to shareholders.
44 601 715 €
29 098 511 €
1 181 414 €
1 153 186 €
906 447 €
2.6%
The debt ratio (= Financial debt / Equity x 100) stands at 58%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 3%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.5 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 1.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
57.813%
2.709%
1.844%
2.533
35.8%
In 2022, the debt ratio of MBBS (57.81) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2022, the financial autonomy of MBBS (2.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2022, the repayment capacity of MBBS (2.53) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 96.57. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.3x. Coverage is limited: any activity downturn would jeopardize interest payments.
96.568
1.262
In 2022, the liquidity ratio of MBBS (96.57) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2022, the interest coverage of MBBS (1.3x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 756 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 850 days. Excellent situation: suppliers finance 94 days of the operating cycle (retail model). Inventory turnover is 5 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 818 days of revenue, i.e. 101.3 M€ to permanently finance. Over 2016-2022, WCR increased by +48%, requiring additional financing.
101 320 378 €
756 j
850 j
5 j
818 j
Based on 85 transactions of similar company sales
(all years),
the value of MBBS is estimated at
5 153 078 €
(range 2 845 496€ - 14 125 056€).
With an EBITDA of 1 181 414€, the sector multiple of 1.0x is applied.
The price/revenue ratio is 0.32x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MBBS with other companies in the same sector:
Voir toutes les statistiques du secteur Autres intermédiaires du commerce en produits divers
The revenue of MBBS in 2022 is 44.6 M€.
Yes, MBBS generated a net profit of 906 k€ in 2022.
The headquarters of MBBS is located in PARIS (75002), in the department Paris.
The tax return of MBBS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MBBS operates in the sector Autres intermédiaires du commerce en produits divers (NAF code 46.19B). See the 'Sector positioning' section above to compare the company with its competitors.